Published in Influenza Other Respir Viruses on May 01, 2010
Overexpressing mouse model demonstrates the protective role of Muc5ac in the lungs. Proc Natl Acad Sci U S A (2012) 1.17
Defective interfering influenza virus RNAs: time to reevaluate their clinical potential as broad-spectrum antivirals? J Virol (2014) 0.92
Comparison of the protection of ferrets against pandemic 2009 influenza A virus (H1N1) by 244 DI influenza virus and oseltamivir. Antiviral Res (2012) 0.91
Cloned defective interfering influenza virus protects ferrets from pandemic 2009 influenza A virus and allows protective immunity to be established. PLoS One (2012) 0.86
Cloned Defective Interfering Influenza RNA and a Possible Pan-Specific Treatment of Respiratory Virus Diseases. Viruses (2015) 0.83
Avian influenza H5 hemagglutinin binds with high avidity to sialic acid on different O-linked core structures on mucin-type fusion proteins. Glycoconj J (2014) 0.80
A CRISPR Activation Screen Identifies a Pan-avian Influenza Virus Inhibitory Host Factor. Cell Rep (2017) 0.75
Avian flu: influenza virus receptors in the human airway. Nature (2006) 11.28
Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science (2009) 8.61
Molecular basis for the generation in pigs of influenza A viruses with pandemic potential. J Virol (1998) 8.44
Early alterations of the receptor-binding properties of H1, H2, and H3 avian influenza virus hemagglutinins after their introduction into mammals. J Virol (2000) 8.28
The structure and receptor binding properties of the 1918 influenza hemagglutinin. Science (2004) 7.74
Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc Natl Acad Sci U S A (2004) 7.18
H5N1 Virus Attachment to Lower Respiratory Tract. Science (2006) 6.34
Avian influenza A viruses differ from human viruses by recognition of sialyloligosaccharides and gangliosides and by a higher conservation of the HA receptor-binding site. Virology (1997) 4.96
Human and avian influenza viruses target different cells in the lower respiratory tract of humans and other mammals. Am J Pathol (2007) 4.86
A single amino acid substitution in 1918 influenza virus hemagglutinin changes receptor binding specificity. J Virol (2005) 4.71
Defective interfering viruses. Annu Rev Microbiol (1973) 4.21
Receptor binding properties of human and animal H1 influenza virus isolates. Virology (1989) 3.98
Inefficient transmission of H5N1 influenza viruses in a ferret contact model. J Virol (2007) 3.79
Tropism of avian influenza A (H5N1) in the upper and lower respiratory tract. Nat Med (2007) 3.75
Influenza virus receptor specificity and cell tropism in mouse and human airway epithelial cells. J Virol (2006) 3.60
Sialyloligosaccharides of the respiratory epithelium in the selection of human influenza virus receptor specificity. Acta Histochem Suppl (1990) 3.12
Receptor specificity of influenza A viruses correlates with the agglutination of erythrocytes from different animal species. Virology (1997) 3.10
Infection of human airway epithelium by human and avian strains of influenza a virus. J Virol (2006) 3.02
Recent avian H5N1 viruses exhibit increased propensity for acquiring human receptor specificity. J Mol Biol (2008) 3.00
Amino acid 226 in the hemagglutinin of H9N2 influenza viruses determines cell tropism and replication in human airway epithelial cells. J Virol (2007) 2.89
Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium. J Virol (2005) 2.65
Receptor binding specificity of recent human H3N2 influenza viruses. Virol J (2007) 2.45
Sialic acid receptor detection in the human respiratory tract: evidence for widespread distribution of potential binding sites for human and avian influenza viruses. Respir Res (2007) 2.45
Differences in sialic acid-galactose linkages in the chicken egg amnion and allantois influence human influenza virus receptor specificity and variant selection. J Virol (1997) 2.38
Effects of egg-adaptation on the receptor-binding properties of human influenza A and B viruses. Virology (1999) 2.31
Studies of the binding properties of influenza hemagglutinin receptor-site mutants. Virology (1998) 1.95
Host-mediated selection of influenza virus receptor variants. Sialic acid-alpha 2,6Gal-specific clones of A/duck/Ukraine/1/63 revert to sialic acid-alpha 2,3Gal-specific wild type in ovo. J Biol Chem (1985) 1.91
Structure of the complex oligosaccharides of fetuin. J Biol Chem (1979) 1.75
Receptor-binding properties of modern human influenza viruses primarily isolated in Vero and MDCK cells and chicken embryonated eggs. Virology (2003) 1.70
Receptor specificity of influenza virus influences severity of illness in ferrets. Vaccine (1995) 1.62
The quail and chicken intestine have sialyl-galactose sugar chains responsible for the binding of influenza A viruses to human type receptors. Glycobiology (2007) 1.37
Receptor-binding properties of swine influenza viruses isolated and propagated in MDCK cells. Virus Res (2005) 1.30
A surface plasmon resonance assay for the binding of influenza virus hemagglutinin to its sialic acid receptor. Virology (1996) 1.29
Human trachea primary epithelial cells express both sialyl(alpha2-3)Gal receptor for human parainfluenza virus type 1 and avian influenza viruses, and sialyl(alpha2-6)Gal receptor for human influenza viruses. Glycoconj J (2006) 1.22
Structural determination of gangliosides that bind to influenza A, B, and C viruses by an improved binding assay: strain-specific receptor epitopes in sialo-sugar chains. Virology (1992) 1.18
Effective replication of human influenza viruses in mice lacking a major alpha2,6 sialyltransferase. Virus Res (2007) 1.17
Ligand recognition by influenza virus. The binding of bivalent sialosides. J Biol Chem (1991) 1.15
Proton nuclear magnetic resonance studies of the binding of sialosides to intact influenza virus. Virology (1992) 1.10
Infection of human airway epithelia with H1N1, H2N2, and H3N2 influenza A virus strains. Mol Ther (2001) 1.09
Influenza virus protecting RNA: an effective prophylactic and therapeutic antiviral. J Virol (2008) 1.02
Binding kinetics of influenza viruses to sialic acid-containing carbohydrates. Glycoconj J (2007) 0.99
Interfering vaccine (defective interfering influenza A virus) protects ferrets from influenza, and allows them to develop solid immunity to reinfection. Vaccine (2006) 0.94
Attachment of infectious influenza A viruses of various subtypes to live mammalian and avian cells as measured by flow cytometry. Virus Res (2007) 0.92
Influenza A virus infection of primary differentiated airway epithelial cell cultures derived from Syrian golden hamsters. Virology (2006) 0.87
The C-terminal tail of the gp41 transmembrane envelope glycoprotein of HIV-1 clades A, B, C, and D may exist in two conformations: an analysis of sequence, structure, and function. Virology (2005) 1.05
Characterization of a human immunodeficiency virus type 1 pre-integration complex in which the majority of the cDNA is resistant to DNase I digestion. J Gen Virol (2002) 1.03
Influenza virus protecting RNA: an effective prophylactic and therapeutic antiviral. J Virol (2008) 1.02
A novel broad-spectrum treatment for respiratory virus infections: influenza-based defective interfering virus provides protection against pneumovirus infection in vivo. Vaccine (2011) 1.01
A region of the C-terminal tail of the gp41 envelope glycoprotein of human immunodeficiency virus type 1 contains a neutralizing epitope: evidence for its exposure on the surface of the virion. J Gen Virol (2003) 0.99
Interfering vaccine: a novel antiviral that converts a potentially virulent infection into one that is subclinical and immunizing. Vaccine (2004) 0.95
Comparison of the protection of ferrets against pandemic 2009 influenza A virus (H1N1) by 244 DI influenza virus and oseltamivir. Antiviral Res (2012) 0.91
In vivo antiviral activity: defective interfering virus protects better against virulent Influenza A virus than avirulent virus. J Gen Virol (2006) 0.91
Defective interfering influenza A virus protects in vivo against disease caused by a heterologous influenza B virus. J Gen Virol (2011) 0.91
Binding of an influenza A virus to a neomembrane measured by surface plasmon resonance. Bioorg Med Chem (2004) 0.86
Cloned defective interfering influenza virus protects ferrets from pandemic 2009 influenza A virus and allows protective immunity to be established. PLoS One (2012) 0.86
Valency of antibody binding to enveloped virus particles as determined by surface plasmon resonance. J Virol (2003) 0.84
Analysis of a 17-amino acid residue, virus-neutralizing microantibody. J Gen Virol (2005) 0.84
Part of the C-terminal tail of the envelope gp41 transmembrane glycoprotein of human immunodeficiency virus type 1 is exposed on the surface of infected cells and is involved in virus-mediated cell fusion. J Gen Virol (2005) 0.84
Defective interfering virus protects elderly mice from influenza. Virol J (2011) 0.83
An antibody specific for the C-terminal tail of the gp41 transmembrane protein of human immunodeficiency virus type 1 mediates post-attachment neutralization, probably through inhibition of virus-cell fusion. J Gen Virol (2005) 0.81
The host-range tdCE phenotype of Chandipura virus is determined by mutations in the polymerase gene. J Gen Virol (2013) 0.75